GlaxoSmithKline
NEWS
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Microsoft announced that Emma Walmsley, chief executive officer of GlaxoSmithKline, had been nominated to the company’s board of directors.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the United States, the company said.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
On Tuesday, the U.K. pharma giant optioned to license an antisense treatment from Ionis Pharmaceuticals following positive Phase II results in chronic hepatitis B virus infection.
ViiV Healthcare’s two-month injection proved to be as effective as monthly injections for HIV treatment that are currently on the market, the GlaxoSmithKline subsidiary said this morning as it continues to position itself for a leading share of the market alongside Gilead Sciences.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
JOBS
IN THE PRESS